Nitrosamine Testing & Risk Assessments

Nitrosamines are chemical compounds classified as probable human carcinogens. Regulatory bodies like the FDA and EMA require that nitrosamines in drug products be controlled at very low levels to ensure patient safety. Even trace amounts above acceptable intake limits may trigger recalls or delays in development.

Frequently monitored nitrosamines include NDMA (N-nitrosodimethylamine), NDEA (N-nitrosodiethylamine), NMBA (N-nitrosomethyl-4-aminobutyric acid), and NEIPA (N-nitrosoethylisopropylamine). Each has strict acceptable intake limits set by global regulators. Testing methods must reliably detect these compounds at sub-ppb levels.

Both the FDA and EMA have issued guidance requiring risk assessments and confirmatory testing for nitrosamines. These regulations specify acceptable intake limits, recommended analytical methods, and timelines for compliance. Non-compliance can result in regulatory action or product recalls.

The gold standard technique is LC-MS/MS, which offers the sensitivity and selectivity required for trace-level detection. Other methods, like GC-MS, can be applied depending on volatility and sample type.

We test drug substances, drug products, excipients, and even water and raw materials. Each matrix requires tailored sample preparation to minimize interferences and ensure reliable results.

The NAP is a stress test that determines whether a compound or excipient can form nitrosamines under nitrosating conditions. This proactive approach helps companies identify and mitigate risks early in development.

Our validated LC-MS/MS assays achieve detection limits down to parts-per-trillion (ppt) for compounds like NDMA. This ensures compliance with stringent FDA and EMA acceptable intake thresholds.

Typical turnaround time is 2–4 weeks, depending on project scope and sample type. For urgent cases, we offer expedited testing to help clients meet regulatory deadlines.

Yes. Many nitrosamines are unique to a specific API or manufacturing process. We specialize in custom LC-MS/MS method development and validation tailored to each compound.

If nitrosamines exceed FDA or EMA thresholds, companies must investigate the root cause, implement corrective actions, and may need to recall products. Proactive testing reduces the risk of costly delays or regulatory action.

Yes. Certain excipients and contaminated water can introduce precursors such as amines or nitrites, which react to form nitrosamines. We test excipients and water via ion chromatography and LC-MS/MS to identify risks.

We combine deep expertise in LC-MS/MS, regulatory compliance (ICH Q2(R2), FDA, EMA), and experience across APIs, drug products, excipients, and packaging. Our team provides not just data, but actionable insights to support regulatory submissions and risk mitigation.